Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients

Glioblastoma is a dreadful disease with very poor prognosis, median overall survival being <2 years despite standard-of-care treatment. This has led to the development of alternative strategies, among which immunotherapy is being actively tested. In particular, many clinical trials of therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutoit, Valérie, Philippin, Géraldine, Widmer, Valérie, Marinari, Eliana, Vuilleumier, Aurélie, Migliorini, Denis, Schaller, Karl, Dietrich, Pierre-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034105/
https://www.ncbi.nlm.nih.gov/pubmed/32117743
http://dx.doi.org/10.3389/fonc.2020.00089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034105/
https://www.ncbi.nlm.nih.gov/pubmed/32117743
http://dx.doi.org/10.3389/fonc.2020.00089

Ejemplares similares